目的 评价第3代表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（EGFR-TKI）奥希替尼治疗ⅠB～ⅢA期完全切除EGFR突变的非小细胞肺癌（NSCLC）患者的成本-效果。方法 建立动态Markov模型获得的质量调整生命年（QALYs）。采用成本-效果分析法，以增量成本-效果比（ICER）为指标，评价奥希替尼用于ⅠB～ⅢA期完全切除EGFR突变的NSCLC患者辅助治疗的成本-效果，并进行敏感性分析。结果 在成本-效果分析中，与安慰剂组相比，奥希替尼组提高了0.553QALYs，治疗费用提高了150 854.42元，ICER值为273 006.87元/QALY。结论 奥希替尼在中国人群中治疗ⅠB～ⅢA期完全切除EGFR突变非小细胞肺癌不存在经济学优势。

Objective To evaluate the cost-effectiveness of osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR-TKI), as adjuvant therapy for patients with completely resected stage IB—IIIA EGFR-mutated nonsmall cell lung cancer (NSCLC). Methods A dynamic Markov model was developed to estimate quality-adjusted life years (QALYs). Cost-effectiveness analysis was performed using the incremental cost-effectiveness ratio (ICER) as the primary indicator. Sensitivity analyses were conducted to assess the robustness of the results. Results In the cost-effectiveness analysis, compared with the placebo group, the osimertinib group provided an additional 0.553 QALYs at an incremental cost of CNY 150 854.42, resulting in an ICER of CNY 273 006.87 per QALY gained. Conclusion Osimertinib does not demonstrate economic advantages in the Chinese population for adjuvant therapy of stage IB—IIIA EGFR-mutated NSCLC.

R979.1

辽宁省科学技术计划应用基础研究项目（2022JH2/101300093）